Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Argenx Se ADR
(NQ:
ARGX
)
430.04
-14.90 (-3.35%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Argenx Se ADR
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Argenx's Vyvgart To 'Achieve Blockbuster Status,' This Analyst Says With 6% Price Target Hike
July 29, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 29, 2022
July 29, 2022
Via
Benzinga
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
July 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
argenx: Q2 Earnings Insights
July 28, 2022
argenx (NASDAQ:ARGX) reported its Q2 earnings results on Thursday, July 28, 2022 at 01:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Recap: argenx Q2 Earnings
July 28, 2022
argenx (NASDAQ:ARGX) reported its Q2 earnings results on Thursday, July 28, 2022 at 01:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
What 5 Analyst Ratings Have To Say About argenx
July 25, 2022
Analysts have provided the following ratings for argenx (NASDAQ:ARGX) within the last quarter:
Via
Benzinga
argenx announces Extraordinary General Meeting of Shareholders on September 8, 2022
July 28, 2022
From
argenx SE
Via
GlobeNewswire
argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update
July 28, 2022
From
argenx SE
Via
GlobeNewswire
Piper Sandler Maintains Overweight Rating for argenx: Here's What You Need To Know
July 25, 2022
Piper Sandler has decided to maintain its Overweight rating of argenx (NASDAQ:ARGX) and raise its price target from $415.00 to $425.00. Shares of argenx are trading up 1.84% over the last 24 hours, at...
Via
Benzinga
SVB Sees Strategic Value In This Stock As M&A Target In Autoimmune Space
May 24, 2022
Via
Benzinga
Golden Cross Appears Before argenx Investors
May 16, 2022
If history is any guide, there may be good fortune ahead for shares of argenx (NASDAQ:ARGX). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the...
Via
Benzinga
Argenx's Vyvgart Meets Primary Goal In Late-Stage Bleeding Disorder Study
May 05, 2022
Via
Benzinga
Recap: argenx Q1 Earnings
May 05, 2022
argenx (NASDAQ:ARGX) reported its Q1 earnings results on Thursday, May 5, 2022 at 01:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Argenx's Vyvgart Long-Term Treatment Shows Improved gMG Disease Scores
April 05, 2022
Argenx SE (NASDAQ: ARGX) announced
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
May 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2022
May 03, 2022
Upgrades
Via
Benzinga
Recap: argenx Q4 Earnings
March 03, 2022
argenx (NASDAQ:ARGX) reported its Q4 earnings results on Thursday, March 3, 2022 at 01:00 AM. Here's what investors need to know about the announcement. Earnings argenx...
Via
Benzinga
argenx's Earnings: A Preview
March 02, 2022
argenx (NASDAQ:ARGX) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts estimate...
Via
Benzinga
What 8 Analyst Ratings Have To Say About argenx
January 18, 2022
Analysts have provided the following ratings for argenx (NASDAQ:ARGX) withi...
Via
Benzinga
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
April 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
April 01, 2022
From
argenx SE
Via
Business Wire
The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale
March 23, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx
March 22, 2022
Piper Sandler noted that Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) recently filed 10-K mentions funding of $25 million from a "pharmaceutical...
Via
Benzinga
Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular Disorder
March 22, 2022
Argenx SE (NASDAQ: ARGX) ) has
Via
Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout
March 22, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
March 22, 2022
From
argenx SE
Via
Business Wire
What 8 Analyst Ratings Have To Say About argenx
March 07, 2022
argenx (NASDAQ:ARGX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 4...
Via
Benzinga
The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug
January 20, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eisai Announces Publication Of Positive Data On Lenvima-Keytruda Combo In...
Via
Benzinga
argenx Announces VYVGART™ Approval in Japan for the Treatment of Generalized Myasthenia Gravis
January 20, 2022
From
argenx
Via
Business Wire
Earnings Scheduled For March 3, 2022
March 03, 2022
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.